Results 111 to 120 of about 9,247 (168)

Leveraging AI to Evaluate Minimal Residual Disease Endpoint Surrogacy in Multiple Myeloma. [PDF]

Cancer Res Commun
Ren Z, Zhao Z, Cowan AJ, Ma W, Xie E, Shi Q.   +5 more
europepmc   +1 more source

Scleredema Associated With IgG/κ Monoclonal Gammopathy of Clinical Significance Successfully Treated With Daratumumab Monotherapy: A Case Report. [PDF]

EJHaem
Marcolongo D, Bressan A, Zanatta E, Alaibac MSA, Gianesello I, Binotto G, Pavan L, Tos APD, Trentin L, Vianello F.   +9 more
europepmc   +1 more source

Advancing multiple myeloma therapy: A systematic analysis of corticosteroids and monoclonal antibodies as dual therapeutic agents. [PDF]

World J Methodol
Alam F, Siddiqui H, Nihal A, Andleeb M, Zaman AQU, Khushk MI, Hussain F, Rai R, Fatima FB, Kumar D, Rizvi SAFA, Jabeen S, Jawed I, Qadir U, Zakeri MA.   +14 more
europepmc   +1 more source

Daratumumab in high-risk MGUS and low-risk smoldering myeloma: results of the Phase II D-PRISM study. [PDF]

Nat Commun
Nadeem O, Aranha MP, Redd RA, Koontz M, Matous JV, Yee AJ, Zonder JA, Kin A, Magidson S, Lightbody ED, Wu T, Chabrun F, Alberge JB, Dutta AK, Perry J, Sturtevant A, Rahmat M, Tsuji J, Davie C, Ricciardi C, Arters F, Marto M, Bergeron A, Rosenblatt J, O'Donnell EK, Mouhieddine TH, Pantano L, Laubach JP, Richardson PG, Getz G, Trippa L, Sklavenitis-Pistofidis R, Ghobrial IM.   +32 more
europepmc   +1 more source

Clinical factors associated with venous thromboembolism in multiple myeloma patients treated with daratumumab. [PDF]

Discov Med (Singap)
Subramanian NG, Aung FM, Hunzeker ZE, Patel KK, Lee HC, Jin S, Young E, Bassett RL, Rojas Hernandez CM.   +8 more
europepmc   +1 more source

Safety of MMR vaccination for patients with myeloma receiving daratumumab after autologous stem cell transplantation. [PDF]

Blood Neoplasia
Davis JA, McElwee J, Gonzalez R, Julian K, Nachar VR, Snyder J, Mahmoudjafari Z, Granger K, Warrick M, Smith D, Baek G, Huang I, Portuguese A, Dima D, Banerjee R, Atrash S, Sborov DW, Grajales-Cruz A, Puglianini OC, Dominick A, Hansen DK, Elsey G, Moore DC.   +22 more
europepmc   +1 more source

Daratumumab plus VRd in Japanese transplant-ineligible/deferred NDMM patients: Japanese subgroup of the CEPHEUS trial. [PDF]

Int J Hematol
Suzuki K, Matsumoto M, Takamatsu H, Kosugi H, Kondo T, Fujisaki T, Facon T, Zweegman S, Ito M, Sakai C, Kanai S, Nakatogawa T, Rowe M, Carson R, Usmani SZ.   +14 more
europepmc   +1 more source

Daratumumab-based first-line therapy benefit multiple myeloma patients in a real-world setting: a multi-center retrospective propensity score-match study. [PDF]

Ann Hematol
Wang Y, Chen X, Liang Q, Wang W, Luo J, Luo L, Feng R, Wei Y, Tian Y, Du X, Huang Z, Hu G, Fu X, Tao S, Zhou J, Peng H, Su Y, Zhang H, Dong M, Lan M, Sun Z, Wang X, Zhou H, Zhong L, Peter Gale R, Liang Y, Xia Z.   +26 more
europepmc   +1 more source

Time and Resource Implications of Subcutaneous Daratumumab-Based versus Intravenous Isatuximab-Based Treatment Regimens for Patients with Newly Diagnosed Multiple Myeloma Who Are Transplant Ineligible. [PDF]

Oncol Ther
Smith E, Camera A, Bird A.
europepmc   +1 more source

MajesTEC-3: Redefining what's possible in multiple myeloma. [PDF]

Clin Hematol Int
Al Hadidi S, Gaballa M.
europepmc   +1 more source